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Abstract
Background: The constitutive androstane receptor (CAR) plays a key role in the control of drug
metabolism and transport by mediating the phenobarbital-type induction of many phase I and II
drug metabolizing enzymes and drug transporters.
Results: We identified transcripts generated by four different alternative splicing events in the
human CAR gene. Two of the corresponding ligand binding domain isoforms demonstrated novel
functional properties: First, CAR(SV3), which is encoded by a transcript containing an lengthened
exon 7, differentially transactivated target gene promoters. Second, CAR(SV2), which results from
the use of an alternative 3' splice site lengthening exon 8, showed ligand-dependent instead of
constitutive interaction with coactivators. Furthermore, alternatively spliced transcripts
demonstrated a tissue-specific expression pattern. In most tissues, only transcripts generated by
alternative splicing within exon 9 were expressed. The encoded variant demonstrated a loss-of-
function phenotype. Correct splicing of exon 8 to exon 9 is restricted to only a few tissues, among
them liver and small intestine for which CAR function has been demonstrated, and is associated
with the induction of CAR expression during differentiation of intestinal cells.
Conclusion: Due to their specific activities, CAR variant proteins SV2 and SV3 may modulate the
activity of reference CAR(SV1). Furthermore, we propose that transcriptional activation and
regulation of splicing of exon 9 may be coupled to ensure appropriate tissue- and differentiation
state-specific expression of transcripts encoding functional CAR protein. Altogether, alternative
splicing seems to be of utmost importance for the regulation of CAR expression and function.
Background
The nuclear receptor CAR (NR1I3) plays a pivotal role in
the induction of drug metabolism and transport by phe-
nobarbital-type inducers. The hepatic expression of phase
I (e.g. CYP2B6, CYP2C9, CYP3A4) and phase II (e.g.
UGT1A1, GSTA1) drug metabolizing enzymes and of
transporters (e.g. MRP2, SLC21A6) is activated by CAR in
response to structurally diverse chemicals [for a review see
[1]]. These are represented by the prototypical inducer
phenobarbital. More recently, endogenous compounds,
like estrogens and bilirubin have been shown to activate
CAR [2,3].
CAR is predominantly expressed in liver and in the intes-
tinal epithelium [4,5]. In the non-induced state, the recep-
tor is largely retained in the cytoplasm by interaction with
the hsp90 complex, which is mediated by the cytoplasmic
CAR retention protein [6]. Treatment with inducers,
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nophen [3,7,8], then stimulates nuclear translocation of
CAR by a poorly understood mechanism. It is only known
that dephosphorylation/phosphorylation steps are
involved [7]. Nuclear translocation does not require direct
binding of the activator to the receptor. Once translocated
to the nucleus, CAR constitutively activates target genes.
The receptor binds to DR3, DR4, DR5, ER6 and ER8
motifs of the general nuclear receptor binding site, which
have been identified in enhancer and promoter regions of
some of the genes regulated [reviewed in [1]]. Usually,
CAR binds to DNA as a heterodimer with RXR.
Binding of a ligand is not required for transcriptional acti-
vation by CAR. The constitutive activity is explained by
the observation that, in contrast to most nuclear receptors,
CAR constitutively interacts with coactivators. However,
ligand binding may further modulate, induce or inhibit,
the transcriptional activity of the receptor. For example,
TCPOBOP and CITCO are agonistic ligands of mouse
CAR and human CAR, respectively [9,10]. Both chemicals
also trigger nuclear translocation [7,10]. On the other
hand, androstane metabolites have been demonstrated to
be inverse agonists of CAR, which inhibit the constitutive
activity of the receptor [11].
Alternative splicing, which occurs in up to 60% of human
genes [12], has been assumed to be one of the major con-
tributors of protein diversity, as it often results in the
expression of protein isoforms. It is also a common phe-
nomenon in the nuclear receptor family. Vitamin D recep-
tor and pregnane X receptor, which are the closest relatives
of CAR, exhibit extensive alternative splicing [13,14]. The
major CAR transcripts expressed in human and mouse
liver are in the size range of 1.3–1.7 kb [4]. One possible
explanation of this broad range of transcript sizes may be
the existence of alternatively spliced transcripts. In fact, an
alternatively spliced CAR transcript, mouse CAR2 has
been identified in mouse liver [15]. Mouse CAR2 is char-
acterized by the out-of-frame deletion of exon 8, which
inactivates the encoded isoform by C-terminal truncation.
Therefore we hypothesized that alternatively spliced tran-
scripts of human CAR may also exist. In this study, we
report the identification of four different alternative splic-
ing events in the human CAR gene, which result in up to
12 different transcripts and potentially encoded isoforms.
In general, alternative splicing impaired the functional
activities of resulting isoforms. However, we identified
distinct novel properties of two of them. Furthermore, we
demonstrate tissue- and differentiation state-specific alter-
native splicing of exon 9.
Results
Identification of human CAR splicing variants
To identify human CAR splicing variants, we cloned the
cDNA of CAR by PCR using oligo(dT)-primed cDNA of an
individual liver and of differentiated Caco-2 cells as tem-
plates. The intestinal Caco-2 cells show an induced CAR
mRNA expression during enterocytic differentiation (see
Fig. 7A). Analyzing the sequences of 23 clones containing
the complete open reading frame, we identified the origi-
nally published CAR cDNA sequence [4] here referred to
as SV1 (8 clones), and the splicing variants SV2 (11
clones), SV4 (3 clones) and SV6 (1 clone) which arise
from three different alternative splicing events (Fig. 1A),
all resulting in ligand binding domain variant CAR pro-
teins. Two of the splicing events were generated using
alternative intronic 3'splice sites, which result in the addi-
tion of 12 bp or 15 bp to the 5'end of exon 7 or exon 8,
respectively. The encoded protein variants are character-
ized by the in-frame insertion of 4 amino acids (VSPT) or
5 amino acids (APYLT), respectively. The third splicing
event, skipping of exon 7, results in an in-frame deletion
of 39 amino acids. While this work was in progress, splic-
ing variants rising from these three splicing events have
been described [16]. By sequencing 10 cDNA clones
encompassing exons 8–9, we identified a fourth alterna-
tive splicing event, which uses an alternative 3'splice site
within exon 9 leading to the out-of-frame deletion of the
first 76 bp of the exon. Consequently, the last 42 amino
acids of CAR are replaced by 7 new amino acids in pro-
teins encoded by splicing variants containing this out-of-
frame deletion (Fig. 1B). If all possible combinations of
the four individual alternative splicing events are taken
into account, 12 different splicing variants of CAR can be
expected which we named SV1-SV12 (Fig. 1A).
All variant proteins of human CAR show a similar 
intracellular distribution
To analyze the impact of the alterations in the LBD gener-
ated by the different splicing events on CAR function, we
constructed CAR expression plasmids encoding variant
proteins which harbor single changes in the LBD:
CAR(SV2), CAR(SV3), CAR(SV4), CAR(SV5) (Fig. 2A). In
addition we constructed an expression plasmid encoding
CAR(SV6), as we found this particular combination of
splicing events in a full length open reading frame cDNA
clone, while we did not find any clone containing only the
insertion of 12 bp in front of exon 7.
We first investigated whether the intracellular distribution
of the variants was altered, compared to reference
CAR(SV1). Transient expression of reference CAR(SV1) in
COS1 cells demonstrated that the protein was accumulat-
ing slightly stronger in the cytoplasm than in the nucleus
(Fig. 2B). All CAR protein variants were distributed simi-
larly. The apparent sizes of the variants were in goodPage 2 of 16
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Genomic organization and structure of alternatively spliced transcripts of human CAR (A) Genomic organization 
of the gene (top) and structure of transcripts (bottom). Exons are depicted as open boxes. Introns are shown by horizontal 
lines. Extension of exons 7 and 8 by use of alternative intronic 3' splice sites is depicted by black boxes. The 5' part of exon 9 
which is deleted by use of an alternative 3'splice site within the exon is shown by a gray box with dotted line. Start and stop 
codons are indicated. TGA* indicates the stop codon of transcripts with the deletion in exon 9. Arrowheads represent the 
position of the indicated primers (see Table 1). Alternatively spliced transcripts are referred to as SV1 to SV12. (B) Detailed 
description of the alternative splicing in exon 9. An alternative 3'splice site resides within exon 9. Use of this site results in the 
out-of-frame deletion of the first 76 bp of the exon. 5' and 3' splice sites are shown in bold lower case letters. Exon sequences 
represented in the transcripts with the deletion are in upper case letters. Encoded amino acids are shown below. The asterisk 
denotes the new stop codon.Page 3 of 16
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approximately 40 kDa for SV1, SV2, SV3 and SV6 and 35
kDa for SV4 and SV5 (Fig. 2B). Furthermore all protein
variants were efficiently and stably expressed in COS1
cells. There was no indication of degradation of particular
isoforms. In conclusion these findings indicate that the
changes within the LBD of the variant CAR proteins nei-
ther influence protein stability nor intracellular
distribution.
CAR protein variants show compromised 
heterodimerization and DNA binding activities
To transactivate the expression of its target genes, CAR has
to bind to its response elements as a heterodimer with
RXRα. Therefore, we analyzed heterodimerization in a
mammalian two hybrid assay. Fig. 3A shows that the LBD
of reference CAR(SV1) and of CAR(SV3) did interact con-
stitutively with the LBD of RXRα. Remarkably, interaction
between RXRα and CAR(SV1) was about 10-fold stronger
than interaction between RXRα and CAR(SV3). The LBD
of all the other variants failed to interact with RXRα. Treat-
ment with the human CAR-specific agonist CITCO [10]
did not influence the interaction of any CAR isoform with
RXRα (data not shown).
To investigate DNA binding of CAR variant proteins to
response elements in the XREM of CYP3A4 [17] and in the
-7.8 kb enhancer of MDR1 (Burk et al., to be published
Structure and intracellular distribution of CAR isoformsFigure 2
Structure and intracellular distribution of CAR isoforms (A) Schematic representation of the indicated CAR isoforms. 
The insertion of 4 or/and 5 additional amino acids in CAR isoforms SV2, SV3 and SV6 is depicted by black boxes. SV4 lacks the 
39 amino acids encoded by exon 7. The last 42 amino acids are replaced by 7 new ones in SV5 (depicted by a light gray box). 
The numbers denote positions of amino acids in reference CAR(SV1). (B) Western Blot analysis of cytoplasmic and nuclear 
proteins of COS1 cells transiently transfected with the expression plasmids of the indicated CAR isoforms. Protein amounts 
were adjusted according to transfection efficiency as estimated by the activity of β-galactosidase encoded by the co-transfected 
expression plasmid pCMVβ. Blots were probed with a CAR-specific antibody.Page 4 of 16
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Impaired heterodimerization and DNA binding activities of CAR isoforms (A) Mammalian two hybrid assays were 
performed in COS1 cells transfected with combinations of an expression plasmid encoding a GAL4-DBD/RXRα–LBD fusion 
protein and expression plasmids encoding VP16-AD/CAR-LBD fusion proteins of CAR isoforms, as indicated. The columns 
show the mean activation factors (± S.D.) of the co-transfected GAL4-dependent reporter through interaction of the GAL4-
DBD/RXRα–LBD fusion protein with VP16-AD/CAR-LBD fusion proteins of the CAR isoforms SV1 to SV6. The activity of the 
GAL4-DBD/RXRα–LBD fusion in the presence of empty expression vector pVP16-AD was designated as 1. (B) Gel electro-
phoretic analysis of [35S]-methionine labeled in vitro synthesized CAR protein isoforms, as indicated. Equal amounts of DNA of 
the respective expression plasmids were transcribed and translated in vitro and proteins were analyzed, as described in Experi-
mental Procedures. (C) Electrophoretic mobility shift assays were performed using in vitro translated proteins bound to a radi-
olabeled doublestranded oligonucleotide corresponding to the DR3 motif of the XREM of CYP3A4. Binding reactions contained 
(+) or lacked (-) the indicated proteins. Complexes of CAR/RXRα heterodimers with the oligonucleotide are marked by an 
arrow.Page 5 of 16
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assays using in vitro translated RXRα and CAR isoforms.
Fig. 3B shows that all CAR protein isoforms were
expressed at comparable levels in vitro. However, only ref-
erence CAR(SV1) was able to bind to the CAR-response
elements DR3 of CYP3A4-XREM (Fig. 3C) and DR4(I) of
MDR1 -7.8 kb enhancer (data not shown) as a het-
erodimer with RXRα.
Gene-specific transactivation activity of isoform CAR(SV3)
To further analyze the functional activity of the CAR LBD
variant proteins, we performed transient co-transfection
assays with enhancer/promoter reporter gene constructs
of CYP2B6, CYP3A4 and MDR1 in COS1 cells. Co-trans-
fection of reference CAR(SV1) expression plasmid
resulted in 11-fold activation of CYP2B6 reporter, 7-fold
activation of CYP3A4 reporter and 12-fold activation of
MDR1 reporter, thus demonstrating constitutive tran-
scriptional activity of reference CAR(SV1) in COS1 cells
(Fig. 4). In contrast, CAR protein variants CAR(SV2),
CAR(SV4), CAR(SV5) and CAR(SV6) were not able to
transactivate any of the reporter gene constructs signifi-
cantly. However, CAR(SV3) significantly transactivated
the CYP2B6 and MDR1 reporter genes 3-fold and 7-fold,
respectively, whereas the CYP3A4 reporter gene was not
significantly activated (Fig. 4).
Constitutive and ligand-induced interaction of CAR 
isoforms with coactivators
CAR demonstrates constitutive interaction with coactiva-
tors, which is further enhanced by ligand binding [9]. We
analyzed the interaction of CAR isoforms with different
coactivators in mammalian two hybrid experiments (Fig.
5). Reference CAR(SV1) showed a strong constitutive
interaction with the coactivators tested. The strongest
interaction was observed with DRIP205 (100-fold). None
of the variant proteins interacted constitutively with coac-
tivators of the p160 family (SRC-1, TIF-2 and ACTR) in
this assay. A weak interaction of CAR(SV3) with DRIP205
was observed, whereas the other isoforms did not interact
with DRIP205. As expected, the human CAR-specific lig-
and CITCO enhanced interaction of reference CAR(SV1)
with each of the coactivators analyzed. This induction was
particularly strong with the coactivators of the p160 fam-
ily (7- to 10-fold) and only modest with DRIP205 (2-
fold). CITCO did not influence the interaction properties
of CAR isoforms SV3, SV4, SV5 and SV6. In contrast, inter-
action of CAR(SV2) with coactivators was strongly
induced. The induction was remarkably strong for the
interaction with DRIP205 (100-fold), thereby reaching
levels of interaction which were obtained with reference
CAR(SV1) in the absence of CITCO.
Tissue specific alternative splicing of exons 8 and 9
Besides the very strong expression in liver, mRNA expres-
sion of human CAR was reported in heart, muscle, kidney
and lung by Northern blot analysis [4]. Consequently, we
were interested in the expression pattern of CAR splicing
variants in different tissues. As transcript SV2 appeared to
represent the most frequent splicing variant among the
sequenced CAR cDNA clones, we analyzed the tissue
expression pattern of transcripts containing an lengthened
exon 8. The assay using primers F1/R1 (Table 1) allowed
us to distinguish between transcripts with and without the
15 bp insertion in front of exon 8, represented by frag-
ments of 136 bp and 121 bp respectively (Fig. 6A). Tran-
scripts with the 15 bp insertion were detected in fetal liver,
kidney, adult liver, lung, trachea and small intestine (Fig.
6A). In contrast CAR transcripts without this insertion
could be detected in every tissue analyzed. RT-PCR with
primers F3/R3 (Table 1), targeting exons 2/3 which
encode parts of the DBD, confirmed the ubiquitous
expression of CAR transcripts in human tissues (data not
shown).
As we demonstrated, that most CAR transcripts encode
non-functional isoforms, we investigated which tissues
may express transcripts encoding functional CAR pro-
teins. RT-PCR with primers F2/R2 (Table 1) allowed to
discriminate between transcripts with and without the 76
bp deletion in exon 9, represented by fragments of 135 bp
and 211 bp, respectively (Fig. 6B). Only fetal liver, kidney,
adult liver, spleen, testis (weakly) and small intestine
showed transcripts without this deletion (Fig. 6B). In con-
trast, transcripts with the deletion in exon 9 were detected
in every tissue with the exception of the small intestine.
However, analysis of further individual small intestine
mucosa samples demonstrated the presence of the 135 bp
fragment in varying amounts (data not shown).
Taken together the results of both assays, the ubiquitous
expression of CAR transcripts can be attributed to the
expression of transcripts with the deletion in exon 9. Thus,
transcripts encoding functional CAR protein are not
expressed in most tissues. This was confirmed exemplarily
by sequencing of lung CAR cDNA clones derived by PCR
of the region corresponding to exons 4–9. All clones ana-
lyzed, just represented transcript SV5.
Expression and alternative splicing of CAR during 
intestinal differentiation of Caco-2 cells
Fig. 7A shows that CAR expression cannot be detected by
Northern blot in intestinal cell lines including subconflu-
ent and confluent Caco-2 TC7. However, if the latter cells
were grown for 15 days post confluence, a very strong
expression of CAR was observed. As enterocytic differenti-
ation of Caco-2 TC7 cells took place when the cell culture
reached confluence [18], we assumed that CAR expressionPage 6 of 16
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CAR(SV3) differentially transactivates promoter reporter genes COS1 cells were co-transfected with enhancer/pro-
moter reporter gene plasmids and expression plasmids encoding CAR isoforms, as indicated. The columns show the mean acti-
vation factors (± S.D.) of the respective reporter genes by the indicated CAR isoforms. The activity of each reporter in the 
presence of empty expression vector pcDNA3 was designated as 1. Statistically significant differences are indicated by asterisks 
(***, p < 0.001).Page 7 of 16
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Constitutive and ligand-dependent coactivator interactions of CAR isoforms Mammalian two hybrid assays were 
performed in COS1 cells transiently transfected with combinations of expression plasmids encoding VP16-AD/CAR-LBD 
fusion proteins and GAL4-DBD/coactivator-RID fusion proteins, as indicated, together with the reporter gene plasmid pGL3-
G5. The columns show the mean activation factors (± S.D.) of the GAL4-dependent reporter through interaction of GAL4-
DBD/coactivator-RID fusion proteins (SRC-1, TIF-2, ACTR, DRIP205) with VP16-AD/CAR-LBD fusion proteins of the CAR 
isoforms SV1 to SV6. Open and filled columns indicate treatment with vehicle Me2SO and CITCO (1 µM), respectively. The 
activity of each GAL4-DBD/coactivator-RID fusion in the presence of the empty expression vector pVP16-AD (VP16) treated 
with Me2SO was designated as 1.Page 8 of 16
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of post-confluent Caco-2 cells was confirmed by analyz-
ing the expression of the intestinal differentiation marker
genes sucrase-isomaltase and alkaline phosphatase.
Expression of both genes was strongly induced by post-
confluent growth (data not shown). Since we could
demonstrate tissue-specific alternative splicing of CAR, it
was of interest to see whether alternative splicing may also
be associated with the induction of CAR expression by dif-
ferentiation. RT-PCR with primers F2/R2 clearly demon-
strated that confluent, undifferentiated Caco-2 cells
predominantly express transcripts with the deletion in
exon 9. However, Caco-2 cells grown for 15 days post con-
fluence showed a strong expression of transcripts without
and a markedly reduced expression of transcript with the
deletion in exon 9 (Fig. 7B). Thus, the strong induction of
CAR expression by enterocytic differentiation was also
associated with a switch in alternative splicing.
Discussion
We here describe the identification of alternatively spliced
transcripts of the human CAR gene which result from four
different splicing events and present a comprehensive
functional characterization of encoded isoforms. While
this work was in progress, isoforms generated by three of
these splicing events have been described [16,19]. In
addition to these, we here describe for the first time the
identification of transcripts generated by use of an alterna-
tive 3' splice site within exon 9. The encoded C-terminally
truncated proteins (e.g. CAR(SV5)) are characterized by
loss of α-helices H10/11 and H12 of the LBD. H12
encodes the AF2 domain, which is essential for ligand-
dependent transactivation of nuclear receptors in general
and also for the constitutive transactivation activity of
CAR [20]. In mouse CAR, the out-of-frame deletion of
exon 8 has similar structural consequences, resulting in
the replacement of the last 78 amino acids by 6 new resi-
dues [15].
Compared to reference CAR(SV1), the intracellular distri-
bution of the variants was not altered. Unexpectedly, even
CAR(SV5) which lacks the last 42 residues did not show
decreased nuclear localization. Loss of these C-terminal
amino acids also removes the xenochemical response sig-
nal (residues 313–319) of CAR, which is essential for
inducer-dependent nuclear translocation in hepatocytes
as well as for constitutive nuclear localization in HEK293
cells [21]. The different result obtained with CAR(SV5) in
COS-1 cells may be due to a specific post-translational
modification which alters functional properties of the
variant. One possibility may be phosphorylation, as the
tripeptide TSR representing the first three new C-terminal
residues of CAR(SV5) fits to the consensus phosphoryla-
tion site recognized by protein kinase C.
We showed that none of the CAR protein variants bind to
DNA as a heterodimer with RXRα. Our data are in agree-
ment with the strongly impaired DNA binding activity
observed recently for the isoforms we here call SV2, SV3,
SV4 and SV6 [16]. The missing DNA binding activity of
CAR(SV5) is in agreement with the observation that the
structural similar mouse CAR2 also did not bind to DNA
[15]. Most likely, this can be attributed to the lack of helix
H10/11 in CAR(SV5), as this helix participates in the het-
erodimerization interface [22]. Altogether, impaired inter-
action with RXRα seems to be the mechanism underlying
the loss of DNA binding of the CAR isoforms.
In agreement with their impaired DNA binding, CAR pro-
tein variants SV2, SV4, SV5 and SV6 did not transactivate
significantly either reporter gene construct tested. In
contrast, CAR(SV3) transactivated the CYP2B6 and MDR1
reporter constructs with 30% and 50% of the activity of
reference CAR(SV1), respectively. However, the isoform
did not activate CYP3A4 significantly. We conclude that
CAR(SV3) may differentially regulate CAR target genes.
Furthermore, CAR(SV3) transactivation activity and inter-
action with RXRα imply that this variant most likely can
Table 1: Oligonucleotides used for RT-PCR analysis
Primer Direction Sequence (5'-3') Exon Detected variants/
Fragment size
F1 forward TGG AGT TGC TCT TTC ACT TCC 7 SV 1, 3, 5, 9/121 bp
R1 reverse TCT CTC TGG GTA ACT CCA GGT C 8 SV 2, 6, 8, 10/136 bp
F2 forward GAC CTG GAG TTA CCC AGA GAG A 8 SV 1, 2, 3, 4, 6, 7/211 bp
R2 reverse ATC TCC TGG AGC AGC GGC ATC AT 9 SV 5, 8, 9, 10, 11, 12/135 bp
F3 forward CTA CCA CTT TAA TGC GCT GAC T 2
SV 1–12 (all variants)/121 bp
R3 reverse CCT CTG AGT CTT GCT GAC TTC 3Page 9 of 16
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impaired DNA binding seen in vitro. CYP2B6 and MDR1
have in common, that in both genes exclusively DR4-type
nuclear receptor binding sites mediate the activation by
CAR (ref. [28], and Burk et al., to be published elsewhere).
In contrast, ER6- and DR3-type binding sites mediate acti-
vation of CYP3A4 [17]. The difference in the type of bind-
ing site may explain the observed gene-specific
transactivation activity of CAR(SV3).
CAR constitutively interacts with coactivators SRC-1, TIF-
2 and ACTR [11,23,24]. Using mammalian two-hybrid
assays, we here show for the first time that reference
CAR(SV1) also interacts constitutively with DRIP205.
Recently, it has been reported that constitutive activity of
CAR results from a few unique structural features which
mimic the function of ligand with respect to reorientation
of H12 into an active conformation [20]. The insertion in
CAR(SV2) is not targeting the respective regions of the
CAR protein, it alters the loop connecting H8 and H9. A
structure-based sequence alignment showed that length
and structural features of the H8/H9 loop are highly con-
served among nuclear receptors. Furthermore, residues of
that loop also participate in the heterodimerization
interface [22]. Interestingly, heterodimerization is also
required for full coactivator recruitment [20]. Thus we sus-
pect that impaired heterodimerization with RXRα causes
the loss of constitutive coactivator interaction of
CAR(SV2) and of the other isoforms, as they all are com-
promised in heterodimerization with RXRα. In contrast,
GST pull-down experiments have shown that CAR protein
variants SV2, SV3, SV4 and SV6 exhibited specific interac-
tions with SRC-1 [16]. These variants may therefore retain
the capability to interact with coactivators in vitro. How-
ever in the more physiological situation of a cell-based
assay, interaction cannot be detected.
The molecular modeling analysis of the human CAR LBD
revealed that the structure of the ligand binding pocket is
probably not altered by the 5 amino acid insert present in
CAR(SV2). The insertion of 4 amino acids and the dele-
tion of 39 amino acids in CAR(SV3) and CAR(SV4),
respectively, are predicted to alter the structure of the lig-
and binding pocket [16]. Likewise CAR(SV5) is probably
Tissue-specific splicing of exons 8 and 9F g re 6
Tissue-specific splicing of exons 8 and 9. Qualitative RT-PCR analysis of the expression of transcripts with alternatively 
spliced exon 8 (A) and exon 9 (B) in the indicated human tissues. Small intestine and colon mucosa samples were derived from 
one individual each. In contrast, the samples of the other tissues represent pools (Human Total RNA Master Panel II, Clon-
tech). The assays were performed as described in Experimental Procedures, with random hexamer primed cDNA of total 
RNA and primer pairs F1/R1 (A) or F2/R2 (B) (see Table 1). SV1, SV2, SV5 denote control reactions performed with DNA of 
the corresponding CAR isoform expression plasmids.Page 10 of 16
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CAR expression and alternative splicing of exon 9 during enterocytic differentiation of Caco-2 TC7 cells. (A) 
Northern Blot analysis with polyadenylated RNA of the indicated cell lines. Caco-2 TC7 cells were analyzed from subconfluent 
(sub), confluent (confl) and 15 days post-confluent (15d pc) cultures. The blot was sequentially hybridized with probes for the 
genes indicated. The arrow marks the major CAR mRNA species of 1.4 to 1.7 kb. (B) Analysis of the expression of transcripts 
with alternatively spliced exon 9 by qualitative RT-PCR with random hexamer primed cDNA of polyadenylated RNA of Caco-
2 TC7 cells cultured until confluence (confl) and for 15 days post-confluent (15d pc). PCR was performed with primers F2/R2 
(Table 1). SV1 and SV5 denote control reactions performed with DNA of the corresponding CAR isoform expression plas-
mids. The lane on the left shows a 50 bp ladder size marker. By mixing DNA of SV1 and SV5 CAR isoform expression plasmids 
in different molar ratios, we confirmed that both fragments were amplified with equal efficiency (data not shown).Page 11 of 16
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CAR LBD has shown that residues of helices H10/11 and
H12 should participate in the ligand binding cavity [20].
Thus we assume that CAR(SV2) is the only variant capable
of ligand binding. Indirect evidence for this assumption is
provided by the observation that among all variants
human CAR-specific ligand CITCO solely induced the
interaction of CAR(SV2) with coactivators. The insert in
CAR(SV2) thus reverts the constitutive coactivator interac-
tion to a ligand-dependent one. Having bound a ligand
seems to induce a sufficiently stabilized active conforma-
tion so that heterodimerization with RXRα is no longer
required. Altogether ligand-dependent coactivator inter-
action suggests a possible functional role for CAR(SV2).
The isoform may sequester coactivators of reference
CAR(SV1) and consequently modulate the activity of the
latter. Thus the ratio of CAR(SV2) and reference
CAR(SV1) may determine CAR-dependent activation by
inducers which also act as ligands.
Alternative splicing of CAR is obviously regulated in a tis-
sue- and differentiation state-specific manner. Splicing
which leads to a lengthened exon 8 occurs in only a few
tissues. In most cases these are the tissues which express
transcripts with correctly spliced exon 9. However both
sets are not completely congruent, thus suggesting an
independent regulation of these two splicing events. Tran-
scripts with the deletion in exon 9 are ubiquitously and
constitutively expressed and appear to be the only ones
expressed in most tissues. The constitutive expression of
these transcripts will be very low in general, as in many tis-
sues and cell lines Northern blot analysis did not detect
any CAR expression or only a very weak one (ref. [4], and
Fig. 8A). Thus, exclusive use of the alternative 3' splice site
within exon 9 appears to be associated with low expres-
sion. Correct splicing of exon 9, which is a prerequisite of
functional CAR expression, is restricted to only a few tis-
sues, among them small intestine and liver where CAR
function has been demonstrated [5,25]. A functional role
of CAR in the other tissues which express transcripts with
correctly spliced exon 9 has not yet been demonstrated.
Interestingly, we observed a switch from use of the alter-
native 3' splice site within exon 9 towards use of the cor-
rect site during enterocytic differentiation of intestinal
Caco-2 cells. Simultaneously, CAR expression was
strongly induced. This raises the intriguing question,
whether transcription and splicing of CAR could be
coordinately regulated. Recently, it has been shown that
activated steroid receptors simultaneously regulate tran-
scription and splicing most likely through the recruitment
of co-regulators involved in both processes [26]. Interest-
ingly, expression of CAR is induced by hormone-activated
GR, which binds to a glucocorticoid response element in
the promoter region of the gene [27]. We propose that the
tissue- and differentiation state-specific correct splicing of
exon 8 to exon 9 may be a transcription-coupled mecha-
nism to restrict expression of functional CAR to the rele-
vant target sites. The low expression which is seen
ubiquitously appears to be associated with the use of the
alternative 3' splice site within exon 9, thus ensuring that
no functional transcripts are produced ectopically. This
may represent a mechanism compensating for inappro-
priate transcription of the CAR promoter.
Conclusions
In general, the LBD isoforms of CAR, which result from
alternative splicing, demonstrate a loss of function
phenotype. However, and in contrast to recent studies
[16,19] we here clearly have shown that two variants
retain distinct functional activities and may therefore exert
specific functions. Furthermore, alternative splicing
within exon 9 appears to be functionally significant, as it
seems to be involved in the control of the tissue- and dif-
ferentiation state-specific expression of functional CAR.
Thus alternative splicing of CAR further adds to the com-
plex regulation of CAR expression and function.
Methods
Materials
All cell culture media, supplements and fetal calf serum
were obtained from Invitrogen (Carlsbad, CA). 6-(4-chlo-
rophenyl)imidazo [2,1-b]thiazole-5-carbaldehyde O-
(3,4-dichlorobenzyl)oxime (CITCO) was obtained from
Biomol (Plymouth, PA).
Cloning of CAR splicing variants by PCR and construction 
of CAR expression plasmids
The open reading frame of CAR (bases 158–1205 of Gen-
bank accession number NM_005122 / GI 32189358) was
amplified by PCR from oligo(dT) primed cDNA samples
of an individual human liver and differentiated Caco-2
cells with primers 5'-ATG AAT TCC ACC ATG GCC AGT
AGG GAA GAT GAG CTG-3', which introduced an EcoRI
site and an optimized Kozak consensus sequence, and 5'-
CGT CTA GAT TAG CTG CAG ATC TCC TGG AGC AG-3',
which introduced an XbaI site and modified the stop
codon to TAA. PCR products of approximately 1000–
1100 bp were purified and digested with EcoRI and XbaI.
The digested fragment was cloned into appropriately
digested pcDNA3 vector (Invitrogen) and the resulting
clones were sequenced. Thus we obtained eukaryotic
expression plasmids (pcDhCAR) for transcripts SV1, SV2,
SV4 and SV6. Part of exons 8–9 (bases 970–1266) was
amplified by PCR from oligo(dT)-primed cDNA of a
human liver with primers 5'-AAT GAA TTC ACC GAC CTG
GAG TTA CCC-3' and 5'-AAT AAG CTT TCC CAC TCC
AGT GTA TCC-3'. The oligonucleotides introduced an
EcoRI and a HindIII restriction site on the 5'- and 3'-ends
of the amplified fragment, respectively. PCR fragments ofPage 12 of 16
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dIII and subsequently cloned into appropriately digested
vector pGEM-7Zf(+) (Promega, Madison, WI). Resulting
clones were sequenced.
The eukaryotic expression plasmid for CAR(SV5) was con-
structed by cloning the 910 bp EcoRI/XmaI insert fragment
of pcDhCAR(SV1) and the 130 bp XmaI/HindIII insert
fragment of a pGEM exon 8–9 clone (see above) contain-
ing the deletion in exon 9 into appropriately digested vec-
tor pcDNA3.1(-) (Invitrogen). The internal XmaI site
resides at position 1067 of the CAR cDNA. To construct a
eukaryotic expression plasmid for transcript SV3, the 15
bp insert lengthening exon 8 was deleted from
pcDhCAR(SV6) by use of the QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to the
recommendations of the manufacturer. The introduction
of the deletion and the absence of other undesired muta-
tions were verified by sequencing.
Other plasmid constructs
The regions encoding the LBD (amino acids 105–348 of
the reference sequence) of CAR protein variants SV1, SV2,
SV3, SV4 and SV6 were amplified by PCR with primers 5'-
TTA GAA TTC CAA CTG AGT AAG GAG CAA GAA GAG-3'
and 5'-TTA TCT AGA GCT GCA GAT CTC CTG GAG C-3',
using the respective expression plasmids as templates. The
region encoding the LBD of CAR(SV5) was amplified by
PCR with the same forward primer and reverse primer 5'-
TTA TCT AGA TGG CAG ACA GGC CCT GGA-3' using
pcDhCAR(SV5) as a template. The primers introduced
EcoRI and XbaI restriction sites on the 5'- and 3'-ends of
the amplified fragment, respectively. The EcoRI /XbaI-
digested PCR fragments were cloned into appropriately
digested vector pVP16 (BD Biosciences Clontech, Palo
Alto, CA), thus generating fusion proteins of the VP16
activation domain and the respective CAR LBD. All con-
structs were verified by sequencing.
The sequence encoding the LBD of human RXRα (amino
acids 226–462) was amplified by PCR using 5'-TTA GAA
TTC GCC AAC GAG GAC ATG CCG-3', which introduced
an EcoRI site and 5'-TTA TCT AGA AGT CAT TTG GTG
CGG CGC C-3', which introduced an XbaI site. The result-
ing PCR fragment was digested with EcoRI and XbaI and
cloned into appropriately digested vector pM (BD Bio-
sciences Clontech). The sequences encoding the receptor
interaction domains (RID) of human coactivators SRC-1,
TIF-2, ACTR and DRIP205 were amplified by PCR from
liver cDNA using appropriate primers and cloned into
vector pM (BD Biosciences Clontech). The cloned regions
encompassed amino acids 583–783 of SRC-1, 583–779 of
TIF-2, 582–782 of ACTR and 527–774 of DRIP205. All the
resulting plasmids encode fusion proteins of the GAL4-
DNA binding domain and the respective regions. The
identities of the cloned DNA fragments were verified by
sequencing.
The reporter gene construct pGL3-G5 was generated by
PCR amplification of the five consensus GAL4 binding
sites and adenovirus E1b minimal promoter of pG5CAT
(BD Biosciences Clontech) and subsequent cloning into
pGL3-Basic (Promega). Enhancer/promoter reporter gene
plasmids of CYP2B6 (pB-1.6k/PB/XREM), CYP3A4
(pGL3-CYP3A4(-7830∆7208-364)) and MDR1 (p-7975/
7013/Tk) have been described previously [28-30]. pB-
1.6k/PB/XREM was kindly provided by E. L. LeCluyse
(School of Pharmacy, University of North Carolina,
Chapel Hill, NC).
Cell culture
COS1 cells were cultivated in Dulbecco's modified Eagle
medium buffered with 25 mM HEPES, supplemented
with 100 units/ml penicillin and 100 mg/ml streptomy-
cin, 2mM L-glutamine, and 10 % fetal calf serum. The
human colon carcinoma cell lines LS174T and LS180
were obtained from the American Type Culture Collection
(Manassas, VA). The human colon carcinoma cell line
Caco-2 TC7 [31] and the human small intestinal cell line
BN [32] were kindly provided by U. Meyer (Division of
Pharmacology/Neurobiology, Biozentrum of the Univer-
sity of Basel, Switzerland) and G. Pang (Royal Newcastle
Hospital, University of Newcastle, Australia), respectively.
The human hepatoblastoma cell line HepG2 was
obtained from B. Sperker (Institute of Pharmacology, Uni-
versity of Greifswald, Germany). LS174T, LS180, Caco-2
TC7 and BN were cultivated in Dulbecco's modified Eagle
medium buffered with 25 mM HEPES, supplemented
with 100 units/ml penicillin and 100 mg/ml streptomy-
cin, 1% non-essential amino acids, 1 mM sodium pyru-
vate, 2 mM L-glutamine and 10% fetal calf serum. HepG2
cells were grown in Minimal Essential Medium, supple-
mented with 100 units/ml penicillin and 100 mg/ml
streptomycin, 2 mM L-glutamine and 10% fetal calf
serum. Cells were grown at 37°C and 5% CO2 in a humid-
ified incubator.
For differentiation experiments, Caco-2 TC7 cells were
plated on collagen I coated dishes (BD Biosciences Dis-
covery Labware, Bedford, MA) and grown in standard
growth medium until confluence was reached. Then, the
medium was replaced by differentiation medium,
containing 5% fetal calf serum and culture was continued
for 15 days with daily exchange of differentiation
medium.
Transient transfections, mammalian two-hybrid and 
reporter gene assays
One day before transfection, COS1 cells were plated in 24-
well plates (BD Biosciences Discovery Labware) at a den-Page 13 of 16
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formed as described [33]. For Two-Hybrid assays, cells
were transfected with 110 ng of the reporter gene plasmid
pGL3-G5, 10 ng of expression plasmids encoding GAL4-
DBD/RXRα-LBD or GAL4-DBD/coactivator-RID fusions,
80 ng of expression plasmids encoding the respective
VP16-AD/CAR-LBD fusions and 20 ng of β-galactosidase
reference plasmid pCMVβ (BD Biosciences Clontech) per
well. In some experiments, cells were subsequently treated
with 1 µM CITCO dissolved in Me2SO or with an equiva-
lent amount (0.1%) of Me2SO only. Luciferase and β-
galactosidase activities were analyzed as described [33].
To identify statistical significant differences, one-way
analysis of variance with Student-Newman-Keuls post test
was performed with the mean values of at least three
independent experiments done in triplicates using Graph-
Pad InStat version 3.05 for Windows 95 (GraphPad Soft-
ware, San Diego, CA).
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were performed as
previously described [30]. Human CAR isoforms and
RXRα protein were synthesized using the CAR isoform
expression plasmids and pCMX-hRXRα (kindly provided
by R. Schüle, Klinik für Tumorbiologie, University of
Freiburg, Germany), respectively and the TNT T7 Quick
Coupled transcription/translation system (Promega). Oli-
gonucleotides for the CYP3A4 DR3-XREM motif were as
follows: sense, 5'-GAT CCG CAG AGG GTC AGC AAG
TTC ATT CAG A-3'; antisense, 5'-GAT CTC TGA ATG AAC
TTG CTG ACC CTC TGC G-3'. Retarded complexes were
quantified with the BAS1800 II phosphor-storage scanner
(Fuji, Kanagawa, Japan) and AIDA software (Raytest,
Straubenhardt, Germany).
Protein analysis
For Western blot analysis of CAR isoforms, COS1 cells
were co-transfected with the respective expression plas-
mids and β-galactosidase plasmid pCMVβ (Clontech)
using calcium phosphate co-precipitation as described
[30]. Cells were harvested 24 hours after transfection and
cell pellets were resuspended in 10 mM Tris-Cl pH 7.8,
5mM KCl, 2mM MgCl2. Cell membranes were lysed by
addition of Nonidet P-40 to 0.5%, and nuclei were col-
lected by centrifugation. The cytoplasmic proteins in the
supernatant were precipitated with acetone. Nuclei and
precipitated cytoplasmic proteins were boiled in 62.5 mm
Tris-Cl pH 6.8, 10% glycerol, 2 % sodium dodecyl sulfate,
5% 2-mercaptoethanol, 0.02% bromphenol blue and
protein samples were resolved on a sodium dodecyl sul-
fate-10% polyacrylamide protein gel. Western blotting
was performed as described [29]. CAR proteins were
detected with a CAR-specific polyclonal antibody [7],
kindly provided by M. Negishi (National Institute of Envi-
ronmental Health Sciences, Research Triangle Park, NC).
Immunoreactive bands were visualized using the chemi-
luminescence substrate SuperSignal West Dura Extended
Duration (Pierce, St Augustin, Germany) and the digital
CCD-camera LAS-1000 (Fuji). Results were analyzed with
AIDA software (Raytest).
CAR proteins were labeled with [35S] methionine by in
vitro synthesis using the TNT T7 Quick Coupled transcrip-
tion/translation system (Promega) and separated on a
sodium dodecyl sulfate-10% polyacrylamide protein gel.
The gel was stained with Coomassie Brilliant Blue, incu-
bated in 0.5 M sodium salicylate and dried. The dried gel
was exposed to phosphor-storage imaging plates and
quantified with the BAS 1800 II phosphor-storage scanner
(Fuji) and AIDA software (Raytest).
Isolation of total RNA and RT-PCR
Total RNA was prepared from human liver samples and
small intestine and colon mucosa samples using the RNe-
asy Mini Kit (Qiagen, Hilden, Germany) as recommended
by the manufacturer. The origin of the human liver and
intestine samples has been described previously [33].
RNA was treated with DNase I to remove contaminating
genomic DNA.
5 µg total or polyadenylated RNA was reverse-transcribed
with Superscript II reverse transcriptase (Invitrogen) with
random hexamer primers according to the standard pro-
tocol of the manufacturer.
Expression of CAR transcripts was analyzed by PCR with
the primers listed in Table 1. PCR was performed with
cDNA corresponding to 500 ng RNA, 1x PCR buffer with
1.5 mM MgCl2 (Roche Diagnostics, Mannheim, Ger-
many), 200 µM each of dATP, dCTP, dGTP and dTTP, 1
µM each of the forward and reverse primers, and 1.25 U
Taq polymerase (Roche Diagnostics). After an initial
denaturation step at 94°C for 2 min, cycling conditions
comprised 30 cycles of 94°C for 30 sec, 65°C for 30 sec,
and 72°C for 30 sec, followed by a final extension step of
72°C for 5 min. PCR products were separated on 10 %
polyacrylamide gels and visualized by staining with ethid-
ium bromide.
Northern blotting
Preparation of polyadenylated RNA and Northern blot
analysis were done as described previously [30]. Radioac-
tive probes were synthesized using the DECAprime II Kit
(Ambion, Austin, TX). To synthesize a probe specific for
human CAR, the cDNA fragment of pcDhCAR(SV1) was
used. The origin of the probe specific for human GAPDH
has been described [30].Page 14 of 16
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